MPS Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript MPS Ltd filed with BSE on 29 Jul 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
MPS Limited reported Q1 FY'27 revenue of INR 224.24 crores, up 20.4% year over year, with EBITDA up 53.0% to INR 76.96 crores and EBITDA margin expanding to 34.3% from 27.0%. Management said all three segments grew, with Research Solutions, Education, and Corporate Learning each showing margin expansion, while Corporate Learning posted its second consecutive quarter of growth. Management reaffirmed the FY'27 outlook to comfortably cross INR 300 crores in EBITDA and discussed the Unbound Medicine acquisition, AI adoption across segments, and a shift toward outcomes-based revenue.
Numbers mentioned
Revenue: INR 224.24 crores (Q1 FY27)
p. 3
“Reported revenue for the quarter was INR 224.24 crores, up 20.4 percent over the same quarter last year.”
Prarthana Agarwal, page 3 of the filed PDF · View the filing
EBITDA: INR 76.96 crores (Q1 FY27)
p. 3
“EBITDA was INR 76.96 crores, up 53.0 percent, with the EBITDA margin expanding to 34.3 percent from 27.0 percent a year ago.”
Prarthana Agarwal, page 3 of the filed PDF · View the filing
Profit after tax: INR 50.39 crores (Q1 FY27)
p. 3
“Profit after tax grew 43.0 percent to INR 50.39 crores, and basic EPS came in at INR 29.70, an all-time Q1 high, up from INR 20.78.”
Prarthana Agarwal, page 3 of the filed PDF · View the filing
Cash and cash equivalents: INR 138.02 crores (as of 30 June 2026)
p. 4
“Total cash and cash equivalents stood at INR 138.02 crores as of 30 June, against borrowings of INR 37.63 crores relating to the facility we drew for the Unbound Medicine acquisition.”
Prarthana Agarwal, page 4 of the filed PDF · View the filing
DSO: 45 days (Q1 FY27)
p. 4
“Collections stayed tight, with DSO improving to 45 days from 51 at the end of March.”
Prarthana Agarwal, page 4 of the filed PDF · View the filing
Research Solutions segment revenue: INR 123.23 crores (Q1 FY27)
p. 4
“Segment revenue was INR 123.23 crores, up 13.2 percent year over year, and it remained the largest part of MPS at 55 percent of total revenue.”
Sukhwant Singh, page 4 of the filed PDF · View the filing
Research Solutions EBITDA margin: 45.1% (Q1 FY27)
p. 4
“EBITDA grew 37.9 percent, well ahead of revenue, and the segment margin widened to 45.1 percent.”
Sukhwant Singh, page 4 of the filed PDF · View the filing
Education segment revenue: INR 73.41 crores (Q1 FY27)
p. 6
“Segment revenue grew 42.2 percent year over year to INR 73.41 crores, and 22.1 percent over the prior quarter, at a 35.1 percent EBITDA margin.”
Sanjeev Talwar, page 6 of the filed PDF · View the filing
Client count: 841, up from 404 (Q1 FY27 vs Q1 FY26)
p. 6
“you can see it most clearly in our client count, which rose across the Company to 841 from 404 a year ago as Unbound's institutional subscribers came onto our books.”
Sanjeev Talwar, page 6 of the filed PDF · View the filing
Corporate Learning segment revenue: INR 27.60 crores (Q1 FY27)
p. 6
“Revenue grew 6.9 percent year over year to INR 27.60 crores, and the story underneath is the margin.”
Soma Bhaduri, page 6 of the filed PDF · View the filing
Corporate Learning EBITDA margin: 25.3% (Q1 FY27)
p. 6
“EBITDA grew 60.7 percent, and the margin expanded to 25.3 percent from under 17 percent a year ago.”
Soma Bhaduri, page 6 of the filed PDF · View the filing
Manuscript acceptance rate: roughly 52 percent
p. 6
“Our controlled work shows a manuscript acceptance rate of roughly 52 percent against an industry baseline near 32 percent.”
Christine Miranda, page 6 of the filed PDF · View the filing
Corporate Learning headcount decline: about 33% year-on-year (Q1 FY27 vs Q1 FY26)
p. 10
“The Corporate Learning headcount is down about 33% year-on-year, and it breaks into 3 parts.”
Soma Bhaduri, page 10 of the filed PDF · View the filing
Research headcount: 2,262 to 2,452 (Q1 FY27 vs prior year)
p. 10
“if you see on the Research side, headcount grew from 2,262 to 2,452 over last year.”
Rahul Arora, page 10 of the filed PDF · View the filing
Education headcount: 799 to 765 (Q1 FY27 vs prior year)
p. 10
“On the Education side, headcount went down from 799 to 765.”
Rahul Arora, page 10 of the filed PDF · View the filing
Unbound Medicine monthly run rate: around $800,000 per month
p. 14
“The monthly run rate is around $ 800,000 per month, and the margins currently are in the range of 18% and 20%, and then we increase from here.”
Prarthana Agarwal, page 14 of the filed PDF · View the filing
Unbound Medicine team size and revenue: 35-person team, $9 million revenue
p. 13
“if you look at the ownership culture at Unbound, it's a 35-person team delivering $ 9 million of revenue and actively growing.”
Rahul Arora, page 13 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
EBITDA — comfortably cross INR 300 crores · FY'27
stated firmly by Prarthana Agarwal
p. 4
“We continue to expect the Company to comfortably cross INR 300 crores in EBITDA in FY'27.”
Prarthana Agarwal, page 4 of the filed PDF · View the filing
Revenue — approximately INR 1,500 crores · FY'28
stated firmly by Rahul Arora
p. 11
“The INR 1,500 crores is for FY’28 next year, and that probably will translate to more like INR 450 crores EBITDA.”
Rahul Arora, page 11 of the filed PDF · View the filing
EBITDA — around INR 450 crores · FY'28
stated firmly by Rahul Arora
p. 11
“So, to summarize: for FY’28, the targets are approximately INR 1,500 crores in revenue and around INR 450 crores in EBITDA.”
Rahul Arora, page 11 of the filed PDF · View the filing
Rule of 50 — clear 50 for the full year · FY'27
stated as an aspiration by Rahul Arora
p. 8
“Rule of 50 is a mark we are hopeful of clearing for the full year, and opening FY'27 on the right side of it tells you the operating model is doing exactly what we built it to do.”
Rahul Arora, page 8 of the filed PDF · View the filing
Corporate Learning exit margin — hold this exit margin as the run rate · rest of FY'27
stated as an aspiration by Soma Bhaduri
p. 7
“Heading into the rest of FY'27, our focus is to hold this exit margin as the run rate, make AI-led delivery the dominant part of the mix, and complete the integration of our legacy entities into one unified Liberate Global brand.”
Soma Bhaduri, page 7 of the filed PDF · View the filing
Corporate Learning steady-state EBITDA margin — 30% EBITDA margin
stated as an aspiration by Soma Bhaduri
p. 14
“In a steady state, the business should operate at a 30% EBITDA margin, and organic growth should be closer to 12%.”
Soma Bhaduri, page 14 of the filed PDF · View the filing
Unbound Medicine EBITDA margin — Rule of 40, mid-20s to late 20s EBITDA margin
stated as an aspiration by Rahul Arora
p. 14
“the expectation is, first, Unbound climbs to Rule of 40, which is hopefully an EBITDA margin in the mid-20s to late 20s, and the balance of it flows through revenue growth.”
Rahul Arora, page 14 of the filed PDF · View the filing
Acquisition size — INR 300 crores to INR 500 crores range
stated as an aspiration by Rahul Arora
p. 11
“So doing an acquisition in the INR 300 crores to INR 500 crores range seems fairly doable between internal cash accruals as well as debt.”
Rahul Arora, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said the talent machine is growing internally and externally, that MPS outperforms the market on external talent success rates, and that culture is maintained through EEE values and an ownership mindset.
Answered by Rahul Arora
Asked by Krushi Parekh: What is driving management-level exits and replacements, and how is the company ensuring operational continuity and cultural alignment across acquired businesses?
p. 9
“If you benchmark us against the market in general, MPS is performing better than the market when it comes to external talent acquisition in terms of success rates.”
Rahul Arora, page 9 of the filed PDF · View the filing
Soma Bhaduri explained headcount reduction in Corporate Learning came from structural redundancy, a shift to variable capacity, and productivity gains from AI, without touching senior client-facing roles.
Answered by Soma Bhaduri
Asked by Krushi Parekh: How is the company ensuring quality is not diluted amid headcount reduction and use of gig workers?
p. 10
“The Corporate Learning headcount is down about 33% year-on-year, and it breaks into 3 parts.”
Soma Bhaduri, page 10 of the filed PDF · View the filing
Rahul Arora said the only pruning was in AJE as already described.
Answered by Rahul Arora
Asked by Kashish Mehta: Why did the client count decline quarter-on-quarter from 906 to 841 - is there client rationalisation?
p. 11
“The only space where there's been pruning in the business is AJE, which Christine already described.”
Rahul Arora, page 11 of the filed PDF · View the filing
Rahul Arora clarified the INR 1,500 crores revenue target is for FY'28, translating to about INR 450 crores EBITDA, while FY'27 guidance remains to comfortably cross INR 300 crores EBITDA.
Answered by Rahul Arora
Asked by Ravi Kumar Naredi: Has focus shifted from the topline target to the EBITDA target?
p. 11
“The INR 1,500 crores is for FY’28 next year, and that probably will translate to more like INR 450 crores EBITDA.”
Rahul Arora, page 11 of the filed PDF · View the filing
Rahul Arora said there is an active pipeline, with a preference for Education-sector assets above $15 million in revenue where AI is a tailwind rather than a threat.
Answered by Rahul Arora
Asked by Ravi Kumar Naredi: Is there a new acquisition in the pipeline?
p. 12
“We're trying our best not to look at assets with less than $ 15 million in revenue.”
Rahul Arora, page 12 of the filed PDF · View the filing
Rahul Arora and Soma Bhaduri discussed synergy opportunities between Liberate and Unbound, Unbound's strong culture despite small team size, and pricing power in the Unbound business.
Answered by Rahul Arora
Asked by Mahesh BP: What new things and challenges has management learned about Unbound Medicine and the sector since acquisition?
p. 12
“the biggest learnings from diligence are the things we have shared with you previously. If your question was about what's new, the new learning was the synergy between Liberate and Unbound”
Rahul Arora, page 12 of the filed PDF · View the filing
Prarthana Agarwal gave the current run rate and margin, and Rahul Arora described the goal of Unbound reaching Rule of 40 and eventually Rule of 50.
Answered by Prarthana Agarwal
Asked by Mahesh BP: What is Unbound Medicine's monthly run rate and margin, and where will these metrics be in 1-2 years?
p. 14
“The monthly run rate is around $ 800,000 per month, and the margins currently are in the range of 18% and 20%, and then we increase from here.”
Prarthana Agarwal, page 14 of the filed PDF · View the filing
Soma Bhaduri attributed the improvement to mix and operating leverage from rebuilding the cost base, and Rahul Arora said forex impact is smaller for Corporate Learning than for Research and Education.
Answered by Soma Bhaduri
Asked by Nachiket Kale: Why has Corporate Learning revenue grown ~7% while PBT nearly doubled, and is there a forex component?
p. 14
“In a steady state, the business should operate at a 30% EBITDA margin, and organic growth should be closer to 12%.”
Soma Bhaduri, page 14 of the filed PDF · View the filing
Rahul Arora said aspirations are higher and that MPS should outperform market growth rates in each segment, citing specific growth-versus-market comparisons for research, education, and corporate.
Answered by Rahul Arora
Asked by Vikas Mhatre: Given AI tailwinds, why isn't organic growth (excluding Unbound) higher than the early teens reported?
p. 15
“Now the markets themselves, research growth at 8%, 9%, we tend to grow at 15%, so we tend to outperform.”
Rahul Arora, page 15 of the filed PDF · View the filing
Rahul Arora explained the shift from distressed-asset acquisitions to targeting assets with inherent strength, applying financial filters like 3-year revenue CAGR of at least 10%, and walking away from culturally misaligned targets.
Answered by Rahul Arora
Asked by Vikas Mhatre: How will the acquisition strategy change to pursue larger deals while maintaining culture and integration quality?
p. 16
“We've seen organic growth return to MPS as we've used this strategy.”
Rahul Arora, page 16 of the filed PDF · View the filing
Rahul Arora, Sukhwant Singh, and Soma Bhaduri described AI applications in Unbound Intelligence, research production workflows, and corporate learning transformation respectively.
Answered by Rahul Arora
Asked by Kaushik Jhawar: Can management share AI use cases across segments where MPS has a real moat?
p. 17
“We are, in fact, scraping things that are behind paywalls from publishers, content assets that are behind paywalls from publishers as well as content assets that we built over the years.”
Rahul Arora, page 17 of the filed PDF · View the filing
Risks flagged
AJE (author solutions) revenue is deliberately smaller as the consumer base resets
p. 5
“As the consumer base finds its new level, the revenue is deliberately smaller, but it is also far more profitable and far higher in quality than the inflated base we carried two years ago.”
Christine Miranda, page 5 of the filed PDF · View the filing
High-stakes subject matter where AI hallucination carries severe consequences
p. 12
“For example, in the nursing world or the medical world, if AI hallucinates, the cost is a patient dying.”
Rahul Arora, page 12 of the filed PDF · View the filing
Organic growth in Corporate Learning has lagged the market growth rate
p. 15
“On the corporate side, the market is growing at 12%, 13%, and we've grown 6%, 7%.”
Rahul Arora, page 15 of the filed PDF · View the filing
Distressed-asset acquisitions previously distracted management from organic growth
p. 16
“what an acquisition of a distressed asset does is that it distracts you from the very organic growth you're pointing us towards because the entire management team is rescuing a new asset every year.”
Rahul Arora, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.